stoxline Quote Chart Rank Option Currency Glossary
  
Coeptis Therapeutics, Inc. (COEP)
10.27  0.46 (4.69%)    05-22 15:59
Open: 10.01
High: 10.4
Volume: 35,798
  
Pre. Close: 9.81
Low: 10
Market Cap: 36(M)
Technical analysis
2025-05-22 3:46:31 PM
Short term     
Mid term     
Targets 6-month :  14.59 1-year :  17.05
Resists First :  12.5 Second :  14.59
Pivot price 9.26
Supports First :  8.64 Second :  6.26
MAs MA(5) :  9.85 MA(20) :  9.11
MA(100) :  9.79 MA(250) :  6.57
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  72.1 D(3) :  68.6
RSI RSI(14): 56.7
52-week High :  13.69 Low :  2.3
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ COEP ] has closed below upper band by 14.6%. Bollinger Bands are 30.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 10.06 - 10.1 10.1 - 10.15
Low: 9.67 - 9.72 9.72 - 9.77
Close: 9.73 - 9.81 9.81 - 9.89
Company Description

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Headline News

Sun, 18 May 2025
(COEP) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Thu, 01 May 2025
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Fri, 25 Apr 2025
Coeptis Therapeutics Subsidiary to Merge With Dogecoin Mining Company - marketscreener.com

Fri, 25 Apr 2025
Coeptis Therapeutics and Z Squared to Merge - citybiz

Fri, 25 Apr 2025
COEP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Coeptis Therapeutics Holdings, Inc. Is Fair to Shareholders - Business Wire

Fri, 25 Apr 2025
Massive Crypto Pivot: Biotech Firm Acquires 9,000 Dogecoin Miners in Industry-Shaking Merger - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
PNK
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 3 (M)
Shares Float 3 (M)
Held by Insiders 19 (%)
Held by Institutions 3.8 (%)
Shares Short 63 (K)
Shares Short P.Month 53 (K)
Stock Financials
EPS -5.1
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.5
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -93.3 %
Return on Equity (ttm) -464.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.7
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -2 (M)
Stock Valuations
PE Ratio -2.02
PEG Ratio 0
Price to Book value 6.85
Price to Sales 0
Price to Cash Flow -5.2
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android